|
|
Article: Razadyne to get generic rival.(RX: RETAIL PHARMACY: Generic Drugs)(Brief article)
- Article from:
- Chain Drug Review
- Article date:
- September 29, 2008
CopyrightCOPYRIGHT 2008 Racher Press, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MONTVALE, N.J. -- Barr Pharmaceuticals Inc. has received final approval from the Food and Drug Administration to manufacture and market a genetic version of Ortho McNeil Janssen's Razadyne (galantamine hydrobromide), 4 mg, 8 mg and 12 mg tablets.
The generic drugs, which are used to treat dementia related to Alzheimer's disease will be made by Barr's subsidiary, Ban Laboratories Inc.
Razadyne tablets had annual sales of approximately $102 million for the 12 months ended June 2008, according to data from IMS Health Inc.
The FDA's approval came a day after U.S. District Court Judge Sue Robinson voided one of Ortho McNeil Janssen's patents on ...